In a special comment, Dr Brendan Shaw, the principal of Shawview Consulting, former CEO of MS and and assistant director-general of the IFPMA, says the PBS and Australian pharmaceutical policy have suffered some shocks in the past but nothing compares to COVID-19. …
Latest Video
New Stories
-
When the Government funds a health technology, the community makes certain assumptions
December 19, 2024 - - Latest News -
If this decision to undermine the TGA reflects a policy decision, be transparent about it
December 18, 2024 - - Latest News -
Race Oncology appoints Opthea founder to its board
December 18, 2024 - - Australian Biotech -
New listings and higher prescription volumes driving PBS spend
December 18, 2024 - - Latest News -
If you have ovarian cancer, genomic testing may open up new treatment option
December 18, 2024 - - BioPharma -
Cartherics secures G-Rex grant to support its ‘in house’ manufacturing program
December 18, 2024 - - Australian Biotech -
Researchers say Australia’s first mRNA vaccine candidate could address COVID ‘immune imprinting’
December 18, 2024 - - Australian Biotech